Ashleigh Palmer
Founder bei Creative Bioventures Corp.
Profil
Ashleigh W.
Palmer was the founder of INO Therapeutics LLC (1997), Provention Bio, Inc. (2016), Celimmune LLC (2015), and Creative Bioventures Corp.
(2002) where he held the titles of President & Chief Executive Officer, President, Chief Executive Officer & Director, Executive Chairman, and President respectively.
Currently, Mr. Palmer is a Non-Executive Director at Third Pole, Inc. Mr. Palmer's former jobs include President, Chief Executive Officer & Director at Unigene Laboratories, Inc. (2010-2013), Chairman & Chief Executive Officer at Restoragen, Inc., Chief Executive Officer at Critical Biologics Corp.
(2006-2010), President, Chief Executive Officer & Director at Tolera Therapeutics, Inc., Director at Tarsa Therapeutics, Inc., and Vice President-Business Development at Ohmeda, Inc. (1992-1997).
Mr. Palmer received an MBA degree from the University of Bradford in 1990 and an undergraduate degree from The University of Manchester in 1984.
Aktive Positionen von Ashleigh Palmer
| Unternehmen | Position | Beginn |
|---|---|---|
Third Pole, Inc.
 Third Pole, Inc. Medical SpecialtiesHealth Technology Third Pole, Inc. engages in the development of cardiopulmonary therapies. Its product is capable of generating nitric oxide from air and electricity. The company is headquartered in San Francisco, CA. | Director/Board Member | - |
Creative Bioventures Corp.
 Creative Bioventures Corp. Miscellaneous Commercial ServicesCommercial Services Creative Bioventures Corp. is a strategic advisory firm. The private company is based in Lebanon, NJ. The company was founded by Ashleigh W. Palmer. | Founder | 01.01.2002 |
Ehemalige bekannte Positionen von Ashleigh Palmer
| Unternehmen | Position | Ende |
|---|---|---|
| PROVENTION BIO, INC. | Founder | 27.04.2023 |
Celimmune LLC
 Celimmune LLC Hospital/Nursing ManagementHealth Services Celimmune LLC is an American company that is not described in the provided metadata. Therefore, no summary can be provided. | Founder | 01.01.2017 |
| UNIGENE LABORATORIES INC | Chief Executive Officer | - |
Critical Biologics Corp.
 Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01.01.2010 |
INO Therapeutics LLC
 INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ. | Chief Executive Officer | 01.12.2001 |
Ausbildung von Ashleigh Palmer
| University of Bradford | Masters Business Admin |
| The University of Manchester | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Unigene Laboratories, Inc.
 Unigene Laboratories, Inc. Pharmaceuticals: OtherHealth Technology Unigene Laboratories, Inc. was a biopharmaceutical company, which engaged in the designing, delivering, manufacturing and development of peptide-based therapeutics. The company was founded by Jay Levy, Ronald S. Levy and Warren P. Levy on October 31, 1980 and was headquartered in Boonton, NJ. | Health Technology |
| Restoragen, Inc. | Health Technology |
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
INO Therapeutics LLC
INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ. | Health Technology |
Tolera Therapeutics, Inc.
 Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tolera Therapeutics, Inc. develops novel therapies and technologies for immune modulation. Its products include anti-aßTCR antibody an immune induction therapy in solid organ transplantation and graft versus host disease. The company was founded by Jake Orville, Maria Siemionow, James J. Herrmann and John J. Puisis in 2007 and is headquartered in Ann Arbor, MI. | Commercial Services |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
| Ohmeda, Inc. | |
Third Pole, Inc.
Third Pole, Inc. Medical SpecialtiesHealth Technology Third Pole, Inc. engages in the development of cardiopulmonary therapies. Its product is capable of generating nitric oxide from air and electricity. The company is headquartered in San Francisco, CA. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Celimmune LLC
Celimmune LLC Hospital/Nursing ManagementHealth Services Celimmune LLC is an American company that is not described in the provided metadata. Therefore, no summary can be provided. | Health Services |
Creative Bioventures Corp.
Creative Bioventures Corp. Miscellaneous Commercial ServicesCommercial Services Creative Bioventures Corp. is a strategic advisory firm. The private company is based in Lebanon, NJ. The company was founded by Ashleigh W. Palmer. | Commercial Services |
